Small-Cell Lung Cancer - Pipeline Review, H2 2015Now Available at iData Insights Small-Cell Lung Cancer - Pipeline Review, H2 2015 Summary Global Markets Direct s, Small-Cell Lung Cancer - Pipeline Review, H2 2015, provides an overview of the Small-Cell Lung Cancers therapeutic pipeline. This report provides comprehensive information on the therapeutic development for Small-Cell Lung Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Small-Cell Lung Cancer and special features on late-stage and discontinued projects. Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease. Scope - The report provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer - The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities The report reviews key players involved in the therapeutics development for Small-Cell Lung Cancer and enlists all their major and minor projects - The report summarizes all the dormant and discontinued pipeline projects - A review of the Small-Cell Lung Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources - Pipeline products coverage based on various stages of development ranging from preregistration till discovery and undisclosed stages - A detailed assessment of monotherapy and combination therapy pipeline projects - Coverage of the Small-Cell Lung Cancer pipeline on the basis of target, MoA, route of administration and molecule type - Latest news and deals relating related to pipeline products Reasons to buy - Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Develop strategic initiatives by understanding the focus areas of leading companies Identify and understand important and diverse types of therapeutics under development for Small-Cell Lung Cancer - Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline - Devise corrective measures for pipeline projects by understanding Small-Cell Lung Cancer pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand
1
business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline. with TOC @ http://www.idatainsights.com/reports-landing-page.php?id=173364/small-celllung-cancer-pipeline-review-h2-2015
Browse
To Get Sample Copy of Report visit @ http://www.idatainsights.com/reports-landingpage.php?id=173364/small-cell-lung-cancer-pipeline-review-h2-2015 Table of Contents
Introduction 12 Global Markets Direct Report Coverage 12 Myelodysplastic Syndrome Overview 13 Therapeutics Development 14 Pipeline Products for Myelodysplastic Syndrome - Overview 14 Pipeline Products for Myelodysplastic Syndrome - Comparative Analysis 15 Myelodysplastic Syndrome - Therapeutics under Development by Companies 16 Myelodysplastic Syndrome - Therapeutics under Investigation by Universities/Institutes 23 Myelodysplastic Syndrome - Pipeline Products Glance 24 Late Stage Products 24 Clinical Stage Products 25 Early Stage Products 26 Myelodysplastic Syndrome - Products under Development by Companies 27 Myelodysplastic Syndrome - Products under Investigation by Universities/Institutes 35 Myelodysplastic Syndrome - Companies Involved in Therapeutics Development 36 4SC AG 36 Acceleron Pharma, Inc. 37 Actinium Pharmaceuticals, Inc. 38 Advancell 39 Agios Pharmaceuticals, Inc. 40 Alnylam Pharmaceuticals, Inc. 41 2
Altor BioScience Corporation 42 Amgen Inc. 43 Apogenix GmbH 44 Arno Therapeutics, Inc. 45 Arog Pharmaceuticals, Inc. 46 Array BioPharma Inc. 47 Astex Pharmaceuticals, Inc. 48 Atara Biotherapeutics, Inc. 49 Bellicum Pharmaceuticals, Inc. 50 Bio-Path Holdings, Inc. 51 BioLineRx, Ltd. 52 Boehringer Ingelheim GmbH 53 Boryung Pharmaceutical Co., Ltd. 54 Boston Biomedical, Inc. 55 Bristol-Myers Squibb Company 56 Celator Pharmaceuticals, Inc. 57 Celgene Corporation 58 Celldex Therapeutics, Inc. 59 Cellerant Therapeutics, Inc. 60 Celyad SA 61 Clevexel Pharma SAS 62 Concert Pharmaceuticals, Inc. 63 Constellation Pharmaceuticals, Inc. 64 Cornerstone Pharmaceuticals, Inc. 65 CrystalGenomics, Inc. 66 CTI BioPharma Corp. 67
3
Cyclacel Pharmaceuticals, Inc. 68 Daiichi Sankyo Company, Limited 69 DiNonA Inc. 70 Eisai Co., Ltd. 71 Eleos Inc. 72 Eli Lilly and Company 73 EpiZyme, Inc. 74 F. Hoffmann-La Roche Ltd. 75 FORMA Therapeutics, Inc. 76 Fujifilm Corporation 77 Gamida Cell Ltd. 78 IGF Oncology, LLC. 79 ImmunoGen, Inc. 80 Incyte Corporation 81 Juno Therapeutics Inc. 82 JW Pharmaceutical Corporation 83 Kainos Medicine, Inc. 84 KaloBios Pharmaceuticals, Inc. 85 Karyopharm Therapeutics, Inc. 86 Kiadis Pharma B.V. 87 Kyowa Hakko Kirin Co., Ltd. 88 Les Laboratoires Servier SAS 89 Lixte Biotechnology Holdings, Inc. 90 medac GmbH 91 MedImmune, LLC 92 MEI Pharma, Inc. 93 Merck & Co., Inc. 94 4
Merus B.V. 95 Millennium Pharmaceuticals, Inc. 96 Mirati Therapeutics Inc. 97 Mirna Therapeutics, Inc. 98 Nemucore Medical Innovations, Inc. 99 Novartis AG 100 Onconova Therapeutics, Inc. 101 Opsona Therapeutics Limited 102 OXiGENE, Inc. 103 Pfizer Inc. 104 Pharma Mar, S.A. 105 Regen BioPharma, Inc. 106 Rich Pharmaceuticals, Inc. 107 Stemline Therapeutics, Inc. 108 Sumitomo Dainippon Pharma Co., Ltd. 109 Sunesis Pharmaceuticals, Inc. 110 Syndax Pharmaceuticals, Inc. 111 Synta Pharmaceuticals Corp. 112 Targazyme, Inc. 113 TetraLogic Pharmaceuticals 114 Teva Pharmaceutical Industries Limited 115 Threshold Pharmaceuticals, Inc. 116 Tragara Pharmaceuticals, Inc. 117 Myelodysplastic Syndrome - Therapeutics Assessment 118 Assessment by Monotherapy Products 118 Assessment by Combination Products 119
5
Assessment by Target 120 Assessment by Mechanism of Action 128 Assessment by Route of Administration 135 Assessment by Molecule Type 137 Drug Profiles 139 (cytarabine hydrochloride + daunorubicin hydrochloride) - Drug Profile 139 (decitabine + E-7727) - Drug Profile 142 4SC-202 - Drug Profile 144 765IGF-MTX - Drug Profile 146 acadesine - Drug Profile 147 AG-120 - Drug Profile 149 ALN-HPN - Drug Profile 151 alpelisib - Drug Profile 152 ALT-803 - Drug Profile 154 Antisense RNAi Oligonucleotide to Inhibit NR2F6 Protein for Oncology - Drug Profile 157 AR-42 - Drug Profile 158 asinercept - Drug Profile 160 atezolizumab - Drug Profile 162 ATIR-101 - Drug Profile 166 azacitidine - Drug Profile 168 BBMPI-03 - Drug Profile 172 BI-836858 - Drug Profile 173 binimetinib - Drug Profile 174 birinapant - Drug Profile 179 BL-8040 - Drug Profile 182 BLI-1301 - Drug Profile 184 bortezomib - Drug Profile 185 6
BP-100101 - Drug Profile 191 BPX-501 - Drug Profile 193 BR-05001 - Drug Profile 195 CC-90007 - Drug Profile 196 CDX-1401 - Drug Profile 199 Cell Therapy to Target Tumor Associated Antigen for Hematopoietic Malignancies - Drug Profile 201 Cell Therapy to Target WT-1, NY-ESO-1, PRAME and Survivin for Oncology - Drug Profile 202 Cell Therapy to Target WT1 for Cancer - Drug Profile 203 cenersen sodium - Drug Profile 204 CG-200745 - Drug Profile 206 CIGB-300 - Drug Profile 207 CMCS-1 - Drug Profile 209 CPI-0610 - Drug Profile 211 CPI-613 - Drug Profile 212 crenolanib besylate - Drug Profile 214 CSC-012 - Drug Profile 216 CTP-221 - Drug Profile 217 CVXL-0056 - Drug Profile 218 CWP-291 - Drug Profile 219 darbepoetin alfa - Drug Profile 221 dasatinib - Drug Profile 223 decitabine - Drug Profile 226 Dendritic Cell Therapy for Hematological Malignancies - Drug Profile 229 Dendritic Cell Therapy for Oncology - Drug Profile 230 Dendritic Cell Therapy to Target WT1 for Oncology - Drug Profile 231 DNP-001 - Drug Profile 232
7
DS-3032 - Drug Profile 233 DSP-7888 - Drug Profile 234 durvalumab - Drug Profile 235 E-6201 - Drug Profile 239 eltrombopag olamine - Drug Profile 241 entinostat - Drug Profile 244 epacadostat - Drug Profile 248 erismodegib - Drug Profile 250 everolimus - Drug Profile 253 evofosfamide - Drug Profile 259 FF-10501 - Drug Profile 267 FT-1101 - Drug Profile 268 galunisertib - Drug Profile 269 ganetespib - Drug Profile 271 Gene Therapy for Oncology - Drug Profile 276 glasdegib - Drug Profile 277 guadecitabine - Drug Profile 279 HDM-201 - Drug Profile 283 Hu8F4 - Drug Profile 284 IMGN-779 - Drug Profile 285 indisulam - Drug Profile 286 Iomab-B - Drug Profile 288 ixazomib citrate - Drug Profile 290 JTCR-016 - Drug Profile 294 KB-004 - Drug Profile 295 KHK-2823 - Drug Profile 297 KM-101 - Drug Profile 298 8
LB-100 - Drug Profile 299 lenalidomide - Drug Profile 301 lirilumab - Drug Profile 306 lurbinectedin - Drug Profile 308 luspatercept - Drug Profile 311 MCLA-?117 - Drug Profile 313 midostaurin - Drug Profile 314 mocetinostat - Drug Profile 316 Monoclonal Antibodies to Target CD16 and CD33 for Oncology - Drug Profile 319 Monoclonal Antibody Conjugate 2 to Target CD45 for Cancer - Drug Profile 320 Monoclonal Antibody Conjugate to Inhibit Protein S100-A9 for MDS - Drug Profile 321 Monoclonal Antibody Conjugate to Target CD45 for Oncology - Drug Profile 322 Monoclonal Antibody for Myelodysplastic Syndrome - Drug Profile 323 MRX-102 - Drug Profile 324 MRX-34 - Drug Profile 326 napabucasin - Drug Profile 328 NiCord - Drug Profile 331 NMI-900 - Drug Profile 332 omacetaxine mepesuccinate - Drug Profile 333 ONC-201 - Drug Profile 336 OPN-305 - Drug Profile 339 OXi-4503 - Drug Profile 341 pacritinib - Drug Profile 343 pembrolizumab - Drug Profile 346 pevonedistat hydrochloride - Drug Profile 355 pexmetinib - Drug Profile 357
9
PIM-447 - Drug Profile 358 pinometostat - Drug Profile 359 pracinostat - Drug Profile 362 quizartinib dihydrochloride - Drug Profile 364 rigosertib sodium - Drug Profile 367 RP-323 - Drug Profile 372 ruxolitinib phosphate - Drug Profile 373 S-055746 - Drug Profile 378 sapacitabine - Drug Profile 379 selinexor - Drug Profile 381 SL-401 - Drug Profile 387 Small Molecule to Inhibit KDM1A for Oncology - Drug Profile 389 Small Molecule to Inhibit SF3B1 for myelodysplastic syndrome - Drug Profile 390 Small Molecules for Oncology - Drug Profile 391 sotatercept - Drug Profile 392 TEN-010 - Drug Profile 394 TG-02 - Drug Profile 395 tosedostat - Drug Profile 398 trametinib dimethyl sulfoxide - Drug Profile 400 treosulfan - Drug Profile 403 TZ-101 - Drug Profile 405 ulixertinib - Drug Profile 407 Vaccine for Oncology - Drug Profile 408 Vaccine to Target Wilms Tumor Protein for Oncology - Drug Profile 409 Vaccine to Target WT1 for Oncology - Drug Profile 410 VAL-1000 - Drug Profile 411 volasertib - Drug Profile 412 10
vorinostat - Drug Profile 415 vosaroxin - Drug Profile 419 WT-4869 - Drug Profile 421 Myelodysplastic Syndrome - Recent Pipeline Updates 422 Myelodysplastic Syndrome - Dormant Projects 662 Myelodysplastic Syndrome - Discontinued Products 667 Myelodysplastic Syndrome - Product Development Milestones 669 Featured News & Press Releases 669 Appendix 675 Methodology 675 Coverage 675 Secondary Research 675 Primary Research 675 Expert Panel Validation 675 Contact Us 675 Disclaimer 676
Read More http://www.idatainsights.com/reports-landing-page.php?id=173364/small-cell-lungcancer-pipeline-review-h2-2015 About Us: iData Insights which operates under Precision Research and Consulting Private Limited is a leading market research information aggregator and marketing research consulting firm. We conduct both primary and secondary research. Our work does not end with research it is also involved in distributing reports for different companies . We provide actionable recommendations and provide our expertise for business success today and tomorrow. It is our goal to be a partner to our clients in the exploration and discovery, and then be their guide in the implementation of changes that will make a difference to their bottom line. ContactUs: iData Insights Tel: 1-866-237-2965
11
Web: http://www.idatainsights.com Email: info@idatainsights.com About iData Insights We work around the clock until our clients are completely satisfied with their promised results. It is our mission to provide timely services coupled with acute client care to create a long-lasting relationship with you. We deliver on our promise to provide results that are essential to the success of your company. We believe that by doing so, we will earn the trust of our clients for future projects
12